Hims & Hers Health, INC

Hims & Hers Health, Inc. announced the resignation of its Chief Accounting Officer, Irene Becklund, effective October 9, 2026, with an advisory role continuing until July 10, 2027.

Hims & Hers Health, Inc. has amended its credit agreement and entered into a Master Receivables Purchase Agreement, establishing a $400 million facility.

Hims & Hers Health, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026, where directors were elected and executive compensation was approved.

Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, significantly expanding its global consumer health platform and reinforcing its long-term financial targets.

Hims & Hers Health, Inc. has priced an upsized $350 million offering of 0.00% convertible senior notes due 2032 to fund international expansion and AI investments.

Hims & Hers Health, Inc. announced first quarter 2026 financial results, reporting revenue of $608 million, a 4% year-over-year increase, and nearly 2.6 million subscribers, while raising full-year revenue and Adjusted EBITDA guidance.

Hims & Hers Health, Inc. reported a 4% increase in total revenue for Q1 2026, reaching $608.1 million, but experienced a significant net loss of $92.1 million.

Hims & Hers Health, Inc. reported a 49% increase in Q3 2025 revenue to $599.0 million, driven by personalized offerings, despite a 79% decrease in quarterly net income.

Hims & Hers Health, Inc. reported robust financial results for Q2 2025, with significant increases in revenue and net income driven by strong subscriber growth and strategic expansion into new offerings.

Hims & Hers Health, Inc. announces a significant increase in revenue and subscribers for the first quarter of 2025, driven by growth in online revenue and the introduction of new weight loss solutions.

Hims & Hers Health, Inc. reports a profitable third quarter with significant revenue growth and the release of a valuation allowance on deferred tax assets.

Hims & Hers Health, Inc. announced a 52% year-over-year increase in revenue for the second quarter of 2024, driven by growth in online sales and subscribers.

Hims & Hers Health, Inc. announced significant revenue and Adjusted EBITDA growth for 2025, alongside international expansion and new product launches, but faces increasing regulatory and legal challenges.

Hims & Hers achieved its first full year of profitability in 2024 and is strategically expanding its capabilities through acquisitions and new specialties.

Hims & Hers Health, Inc. announced a significant 65% increase in revenue for 2023, reaching $872 million, fueled by a 48% growth in subscribers and successful expansion into new health and wellness specialties.

Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc., sold 7,163 shares of common stock on July 17, 2026 for $31.99 per share.

Hims & Hers Health, Inc. Chief Financial Officer, Oluyemi Okupe, reported the sale of 7,163 shares of Class A Common Stock for an average price of $36.4863, executed under a pre-arranged Rule 10b5-1 trading plan.

Chief Medical Officer Patrick Harrison Carroll acquired 25,926 shares of Hims & Hers Health, Inc. through RSU vesting, with 8,310 shares withheld for taxes.

Hims & Hers Health, Inc. CFO Oluyemi Okupe reported the vesting of restricted stock units and subsequent tax-related share withholding.

Chief Policy Officer Deborah M. Autor exercised restricted stock units and sold shares to cover tax obligations.

Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported the vesting of restricted stock units and subsequent sale of shares under a Rule 10b5-1 plan.

Hims & Hers Health, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to be held virtually.

Hims & Hers Health, Inc. announces its 2025 Annual Meeting of Shareholders to be held virtually on June 12, 2025, with voting open until June 11, 2025.

Hims & Hers Health, Inc. has announced its 2025 Annual Meeting of Stockholders to be held virtually on June 12, 2025, along with details on director nominations, executive compensation, and financial performance.

Hims & Hers Health, Inc. has released its proxy statement for the 2024 Annual Meeting of Stockholders, detailing meeting logistics, voting procedures, and proposals to be considered.

Andrew Dudum, CEO of Hims & Hers Health, Inc., has updated his beneficial ownership to 10.3% of the Class A common stock, reflecting a significant insider stake.

Vanguard Capital Management has reported beneficial ownership of over 11.18 million shares, representing 5.01% of Hims & Hers Health Inc.'s common stock.

Susquehanna Investment Group and affiliated entities have reported beneficial ownership of 14,502,395 shares, representing 6.5% of Hims & Hers Health, Inc.'s Class A Common Stock as of March 31, 2026.

Capital World Investors has filed an amendment to its Schedule 13G, reporting beneficial ownership of 2 shares of Hims & Hers Health, Inc. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Hims & Hers Health Inc. following an internal corporate realignment.

JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, reporting a 1.7% beneficial ownership in Hims & Hers Health, Inc.'s Class A common stock.

Capital World Investors has reported a 6.5% beneficial ownership stake in Hims & Hers Health, Inc., holding over 14.3 million shares.